creatine
Small moleculeexperimental
Creatine is an organic compound with the nominal formula (H2N)(HN)CN(CH3)CH2CO2H. It exists in various tautomers in solutions. Creatine is found in vertebrates, where it facilitates recycling of adenosine triphosphate (ATP), primarily in muscle and brain tissue. Recycling is achieved by converting adenosine diphosphate (ADP) back to ATP via donation of phosphate groups. Creatine also acts as a buffer. — Wikipedia
Clinical trial activity
152 trials · 128 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
29
Phase 3
12
Phase 4
10
Earliest trial started May 26, 2000 (NCT00005674)
Timeline
Indications
Approved for
Studied for
- Amyotrophic Lateral Sclerosis · Phase 3
- Anorexia · Phase 3
- Anxiety · Phase 3
- Arsenic · Phase 4
- Athletes · Phase 4
- Bipolar Disorder · Phase 4
- Body Weight · Phase 3
- Breast Neoplasms · Phase 1
- Cachexia · Phase 3
- Colitis, Ulcerative · Early Phase 1
- Critical Illness · Phase 1
- Depression · Phase 4
- Diagnosis, Dual (Psychiatry) · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 1
- Endothelial Cells · Early Phase 1
- Exercise · Phase 1
- Fatigue · Early Phase 1
- Fatigue Syndrome, Chronic · Phase 2
- Follicle Stimulating Hormone · Phase 2
- Health Behavior · Phase 1
- Healthy Volunteers · Early Phase 1
- Huntington Disease · Phase 3
- Hyperhomocysteinemia · Early Phase 1
- Inflammation · Phase 1/Phase 2
- Major Depressive Disorder · Phase 4
- Methamphetamine · Phase 3
- Methicillin-Resistant Staphylococcus aureus · Phase 1
- Muscle Hypotonia · Phase 1
- Muscle Weakness · Phase 3
- Muscular Dystrophy, Duchenne · Phase 3
- Muscular Dystrophy, Facioscapulohumeral · Phase 2
- Neoplasms · Phase 3
- Neuroimaging · Phase 4
- Nutritional Status · Phase 1
- Osteoporosis · Phase 3
- Parkinson Disease · Phase 3
- Peripheral Arterial Disease · Phase 2
- Prostatic Neoplasms · Early Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Sarcopenia · Phase 3
- Schizophrenia · Phase 3
- Sedentary Behavior · Early Phase 1
- Sepsis · Phase 1
- Substance-Related Disorders · Phase 4
- Wounds and Injuries · Phase 1/Phase 2
Mechanism of action
- Creatine kinase B-typeSUBSTRATE
CKB substrate
Chemistry & pharmacology
Loading structure…
SMILES
CN(CC(=O)O)C(=N)N- Mol. weight
- 131.13 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCreatine ↗
- ChEMBLCHEMBL283800 ↗
Also known as
- alpha-methylguanidino acetic acid
- alpha-methylguanidino acetic acid
- (alpha-methylguanido)acetic acid
- (alpha-methylguanido)acetic acid
- ((amino(imino)methyl)(methyl)amino)acetic acid
- ((amino(imino)methyl)(methyl)amino)acetic acid
- creatin
- creatin
- creatine
- creatine
- creatine
- creatine
- creatine
- creatine
- creatine
- creatine ethyl ester
- creatine ethyl ester
- creatine monohydrate
- creatine monohydrate
- creatine nitrate
- creatine nitrate
- dicreatinol sulfate
- kreatin
- kreatin
- methylglycocyamine
- methylglycocyamine
- methylguanidoacetic acid
- n-amidinosarcosine
- n-amidinosarcosine
- n-(aminoiminomethyl)-n-methylglycine
- n-(aminoiminomethyl)-n-methylglycine
- n-carbamimidoyl-n-methylglycine
- n-carbamimidoyl-n-methylglycine
- n-[(e)-amino(imino)methyl]-n-methylglycine
- n-[(e)-amino(imino)methyl]-n-methylglycine
- (n-methylcarbamimidamido)acetic acid
- (n-methylcarbamimidamido)acetic acid
- n-methyl-n-guanylglycine
- n-methyl-n-guanylglycine
- sodium creatine phosphate
- sodium creatine phosphate
- sodium phosphocreatine
- (α-methylguanido)acetic acid
- (α-methylguanido)acetic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07275996 | N/A | Mar 10, 2026 | University of Burgos |
| NCT07310043 | N/A | Jan 1, 2026 | Harvard University |
| NCT07225335 | N/A | Nov 7, 2025 | TSI Group LTD, University of North Carolina at Chapel Hill |
| NCT07029243 | N/A | Oct 31, 2025 | University of California, San Francisco |
| NCT06948149 | N/A | Sep 1, 2025 | Alzheimer Society of Canada, University of Western Ontario |
| NCT06991426 | Phase 4 | Jul 31, 2025 | Federal University of Sao Paulo |
| NCT07233707 | N/A | Jul 24, 2025 | Harokopio University, University of Athens, University of Belgrade |
| NCT06992414 | N/A | Jul 2, 2025 | University of Calgary |
| NCT07027800 | N/A | Jun 2, 2025 | University of North Carolina at Chapel Hill |
| NCT06925880 | N/A | Apr 22, 2025 | Hospital de Mataró |
| NCT06937190 | N/A | Apr 1, 2025 | Ankara Yildirim Beyazıt University |
| NCT06883292 | N/A | Mar 24, 2025 | Lonza |
| NCT06677359 | N/A | Nov 30, 2024 | Fundacion Miguel Servet |
| NCT06675708 | N/A | Nov 30, 2024 | Camilo Jose Cela University |
| NCT06660004 | N/A | Nov 15, 2024 | University of Novi Sad |
| NCT06395506 | N/A | Oct 29, 2024 | University of Texas, Galveston |
| NCT06594406 | N/A | Oct 10, 2024 | Southern Medical University |
| NCT06576466 | N/A | Sep 27, 2024 | Fundació Investigació de les Illes Balears |
| NCT06606704 | N/A | Aug 20, 2024 | Iovate Health Sciences International Inc, University of Regina |
| NCT06604793 | N/A | Aug 20, 2024 | Iovate Health Sciences International Inc, University of Regina |
Showing 20 of 152 trials
Page 1 / 8
Organizations
Research & Development (128)
128 organizations
Page 1 / 7